Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
| Revenue (TTM) | $49.59M |
| Gross Profit (TTM) | $42.21M |
| EBITDA | $-169.86M |
| Operating Margin | -240.50% |
| Return on Equity | -786.00% |
| Return on Assets | -59.40% |
| Revenue/Share (TTM) | $0.62 |
| Book Value | $0.93 |
| Price-to-Book | 6.20 |
| Price-to-Sales (TTM) | 10.69 |
| EV/Revenue | 8.29 |
| EV/EBITDA | -0.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -78.60% |
| Shares Outstanding | $87.87M |
| Float | $70.38M |
| % Insiders | 0.93% |
| % Institutions | 98.27% |
Volatility is currently contracting
Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment wit.
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma.
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem Oncology to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D program and updated Phase 1/2 TARGET-D 101 data.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company's website at www.verastem.com. A.
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
The heavy selling pressure might have exhausted for Verastem (VSTM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in New York City: HCW 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026, 4:00-4:30 pm ET RBC Global Healthcare Conference: Wednesday, May 20, 2026, 9:30-9:55 am ET A live webcast of the fire.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VSTM and any ticker you trade — then tracks every position and per-strategy win rate.
